The introduction of THCV, HHC and HHCV as potential candidates towards the treatment of pancreatic cancer through possible interaction of GPCR pathways that are found within PDAC cells could modulate and contribute to the pro-apoptotic and anti-proliferation properties that these cannabinoids produced in-vitro. The IC50 values of these compounds compared to PARP inhibitors which are known for treating various cancers, are much lower resulting in a more efficient compound for the specific treatment of pancreatic cancer. A semi-SAR study by hydrogenating THCV and producing HHCV, did provide slightly lower IC50 value on specific PDAC cell line. Although the IC50 values are lower compared to other active antineoplastic compounds on the market the treatment of Pancreatic cancer is still evolving and the need to produce antineoplastics is pertinent. Continued SAR and analogs studies are currently being conducted to increase bioavailability and increase IC50 values from micromolar to nanomolar concentrations.